4.6 Article

MicroRNA-132-3p, Downregulated in Myeloid Angiogenic Cells from Hereditary Hemorrhagic Telangiectasia Patients, Is Enriched in the TGFβ and PI3K/AKT Signalling Pathways

Journal

GENES
Volume 13, Issue 4, Pages -

Publisher

MDPI
DOI: 10.3390/genes13040665

Keywords

hereditary hemorrhagic telangiectasia; myeloid angiogenic cells; microRNAs; early endothelial progenitor cells; circulating angiogenic cells; transforming growth factor beta signalling pathway; PI3K; AKT signalling pathway

Funding

  1. Brain Vascular Malformation Consortium (BVMC)
  2. National Institutes of Health (NIH) [U54 NS065705]
  3. NIH Rare Disease Clinical Research Network (RDCRN) through NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS)
  4. NIH Rare Disease Clinical Research Network (RDCRN) through National Institute of Neurological Disorders and Stroke (NINDS)
  5. Nelson Arthur Hyland Foundation
  6. Li Ka Shing Knowledge Institute
  7. Alayne Metrick Fund, Unity Health Toronto, Toronto, ON, Canada

Ask authors/readers for more resources

This study identified dysregulated miRNA expression in MACs of HHT patients, particularly decreased expression of miR-132-3p. The dysregulated miRNAs are significantly enriched in the TGF beta, PI3K/AKT, and Hippo signalling pathways, which may contribute to MAC dysfunction in HHT.
Background. Hereditary hemorrhagic telangiectasia (HHT) is a rare, autosomal dominant genetic disorder characterized by life-threatening vascular dysplasia. Myeloid angiogenic cells (MACs), alternatively called early endothelial progenitor cells or circulating angiogenic cells, do not directly incorporate into developing blood vessels, but augment angiogenesis in a paracrine manner. MAC dysfunction has been reported in HHT. MicroRNAs (miRNAs) regulate cellular function by modulating gene expression post-transcriptionally. To date, the role of miRNAs in HHT MAC dysfunction has not been documented. Objective. The goal of this study was to comparatively profile miRNAs in HHT patient and control MACs to identify dysregulated miRNAs that may be responsible for the observed MAC dysfunction in HHT. Methodology/Results. Twenty-three dysregulated miRNAs (twenty-one upregulated and two downregulated) in HHT MACs were identified with a TaqMan miRNA microarray. Pathway enrichment analysis showed that the dysregulated miRNAs were significantly enriched in pathways involved in HHT pathogenesis, such as the transforming growth factor beta (TGF beta), phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), and Hippo signalling pathways. Furthermore, miR-132-3p was determined to be significantly reduced in HHT MACs compared with controls by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Bioinformatic analysis revealed that miR-132-3p is significantly enriched in the TGF beta and PI3K/AKT signalling pathways, targeting SMAD4, an effector of the TGF beta signalling pathway and RASA1, a negative regulator of the PI3K/AKT signalling pathway, respectively. Conclusion. MiRNA dysregulation, specifically reduced expression of miR-132-3p, in HHT MACs was identified. The dysregulated miRNAs are significantly enriched in the TGF beta, PI3K/AKT, and Hippo signalling pathways. These data suggest that alteration in miRNA expression may impair these pathways and contribute to MAC dysfunction in HHT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available